INAB (IN8bio) OCF Margin %: 0.00% (As of Mar. 2026)


INAB IN8bio Inc INAB
24 GF Score
Price $1.36
View Full Analysis

What is IN8bio OCF Margin %?

IN8bio INAB -0.45% 24 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates INAB with a GF Score™ of 24/100. Among 958 Biotechnology companies, IN8bio ranks worse than 104384.03% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. IN8bio's Cash Flow from Operations for the three months ended in Mar. 2026 was $-4.95 Mil. IN8bio's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, IN8bio's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, IN8bio's current OCF Yield % is -111.46%.

The historical rank and industry rank for IN8bio's OCF Margin % or its related term are showing as below:


INAB's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

IN8bio OCF Margin % Related Terms

IN8bio OCF Margin % Historical Data

* Premium members only.

The historical data trend for IN8bio's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IN8bio OCF Margin % Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

IN8bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
INAB
24GF Score
IN8bio Inc INAB
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IN8bio OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

IN8bio's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-12.712/0
= %

IN8bio's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.947/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
IN8bio (INAB) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on IN8bio and its competitors. According to the industry distribution chart, IN8bio ranks #999999 out of 958 companies in the Biotechnology industry.
Is IN8bio's OCF Margin % too high?
IN8bio's current OCF Margin % is 0.00%. Based on the distribution chart, IN8bio ranks #999999 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IN8bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does IN8bio's OCF Margin % compare to ZIVO and LPCN?
According to the Biotechnology industry distribution chart, IN8bio ranks #999999 out of 958 companies for OCF Margin %. This places IN8bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on IN8bio and its competitors. IN8bio's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IN8bio stock overvalued right now?
IN8bio (INAB) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. IN8bio's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For IN8bio (INAB), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IN8bio Business Description

Address 350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
24GF Score

Get the complete analysis for INAB

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.36
Price